{"filing":{"accession_number":"0001193125-26-424649","cik":"0001816736","ticker":"IRON","company_name":"Disc Medicine, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"d156263d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526424649/d156263d8k.htm"},"events":[{"id":35934,"run_id":33122,"accession_number":"0001193125-26-424649","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Disc Medicine announced positive Phase 3 APOLLO trial results for bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. The company plans to resubmit an NDA to the FDA by end of 2026 with an anticipated decision by mid-2027, representing a material clinical and regulatory milestone for the clinical-stage biopharmaceutical company.","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40168,"accession_number":"0001193125-26-424649","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Disc Medicine announced positive Phase 3 APOLLO trial results for bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. While this is a clinical milestone rather than a financial result or earnings release, it represents a material operational and strategic development for a clinical-stage biopharmaceutical company—the successful completion of a pivotal trial is a key value driver and regulatory milestone that would affect investor assessment of the company's prospects. The disclosure includes plans to resubmit an NDA to the FDA by end of 2026 with an anticipated decision by mid-2027, indicating material progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:08:40.736554+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40169,"accession_number":"0001193125-26-424649","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 3 clinical trial results for bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, supporting the company's development pathway and planned NDA resubmission to the FDA by end of 2026. While this is a significant clinical achievement, it does not fit the specific \"earnings_release\" category (which typically applies to financial results) nor any other defined event type, making \"operational_other\" the most appropriate classification for this material clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:08:40.736554+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40168,"accession_number":"0001193125-26-424649","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Disc Medicine announced positive Phase 3 APOLLO trial results for bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. While this is a clinical milestone rather than a financial result or earnings release, it represents a material operational and strategic development for a clinical-stage biopharmaceutical company—the successful completion of a pivotal trial is a key value driver and regulatory milestone that would affect investor assessment of the company's prospects. The disclosure includes plans to resubmit an NDA to the FDA by end of 2026 with an anticipated decision by mid-2027, indicating material progress toward commercialization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:08:40.736554+00:00","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-10-19"},{"id":40169,"accession_number":"0001193125-26-424649","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 3 clinical trial results for bitopertin in erythropoietic protoporphyria (EPP), meeting all primary and secondary endpoints. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, supporting the company's development pathway and planned NDA resubmission to the FDA by end of 2026. While this is a significant clinical achievement, it does not fit the specific \"earnings_release\" category (which typically applies to financial results) nor any other defined event type, making \"operational_other\" the most appropriate classification for this material clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T11:08:40.736554+00:00","company_name":"Disc Medicine, Inc.","ticker":"IRON","filing_date":"2026-10-19"}]}